Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.98B 3.44B 3.21B 2.95B 5.55B 379B 5.63B 37.71B 14.8B 190B 14.94B 14.61B 627B P/E 2026 *
-45.8x
P/E 2027 * -141x
Enterprise Value 3.86B 3.34B 3.12B 2.86B 5.38B 367B 5.46B 36.58B 14.36B 184B 14.49B 14.18B 609B EV / Sales 2026 *
13.2x
EV / Sales 2027 * 10.6x
Free-Float
98.37%
Yield 2026 *
-
Yield 2027 * -
1 day+5.64%
1 week+10.46%
Current month+10.46%
1 month+19.74%
3 months+69.71%
6 months+58.08%
Current year+53.51%
1 week 21.83
Extreme 21.829
24.96
1 month 20.25
Extreme 20.25
24.96
Current year 12
Extreme 12
24.96
1 year 11.92
Extreme 11.92
24.96
3 years 2.28
Extreme 2.28
24.96
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 08/09/2009
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap.
30/07/26 Sell

Executive/Senior Manager

-1,299 0.0008%
21/07/26 Fiscal year

Founder

1,062,000 0.6636%
16/07/26 Sell

Executive/Senior Manager

-5,000 0.0031%
Change 5-day change 1-year change 3-year change Capi.($)
+5.64%+10.46%+98.80%+272.09% 3.98B
+2.32%+1.94%+70.59%+90.48% 3.8B
+2.09%+55.77%+140.15%-10.07% 2.87B
+4.20%+6.82%+286.83%+332.31% 2.42B
+4.99%+4.72%-25.28%-32.77% 2.27B
+2.20%0.00%+5.49% - 1.26B
+0.70%+7.43%-3.67%+25.65% 934M
-0.32%-5.18%+207.65%-43.47% 919M
+3.09%+3.92%-37.86%-5.07% 532M
-1.90%+9.72%+2.62% - 503M
Average +2.30%+9.36%+74.53%+78.64% 1.95B
Weighted average by Cap. +3.21%+12.66%+96.22%+118.89%

Financials

2026 *2027 *
Net sales 293M 254M 237M 217M 409M 27.91B 415M 2.78B 1.09B 13.99B 1.1B 1.08B 46.24B 359M 310M 290M 266M 500M 34.12B 508M 3.4B 1.33B 17.1B 1.35B 1.32B 56.54B
Net income -85.78M -74.2M -69.29M -63.56M -120M -8.16B -121M -813M -319M -4.09B -322M -315M -13.53B -27.55M -23.83M -22.26M -20.42M -38.4M -2.62B -39.01M -261M -102M -1.31B -103M -101M -4.35B
Net Debt -119M -103M -96.34M -88.38M -166M -11.35B -169M -1.13B -444M -5.69B -448M -438M -18.81B -166M -143M -134M -123M -231M -15.76B -234M -1.57B -616M -7.9B -622M -608M -26.11B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
07/08/26 $24.93 +5.64% 2,495,201
06/08/26 $23.60 -4.07% 2,466,112
05/08/26 $24.60 +0.20% 2,415,866
04/08/26 $24.55 +6.23% 3,291,487
03/08/26 $23.11 +2.39% 2,591,235
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
24.93USD
Average target price
25.07USD
Spread / Average Target
+0.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock